NEW YORK & LONDON & PARIS–(BUSINESS WIRE)–#biopharmaceutical–Regulatory News:
Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) (“Aptorum Group” or the “Company”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2021.
“During the first half of 2021, we remained focused on advancing the development of our therapeutic programs. As announced in early 2021, our ALS-4 program (targeting infections caused by Staphylococcus aureus including MRSA) commenced a Phase 1 clinical study in Canada. We are pleased that 5 total cohorts, which represent the essential part of the single ascending dose (“SAD”) portion of the trial, have been completed without any serious adverse events being observed. On the basis of ALS-4’s favourable safety profile, we are commencing the multiple ascending dose (“MAD”) portion of the trial in Q3, 2021. Our other lead program SACT-1 (targeting neuroblastoma), has also received clearance from the US FDA to commence clinical trials in the United States. SACT-1 will be our second therapeutic program entering into the clinical phase. Our RPIDD program (liquid biopsy based approach to infectious disease rapid diagnostics) is also progressing well and we are very pleased to continue its clinical validation currently in collaboration with A*Star. Finally, we are excited to continue with our efforts of commercialising our NativusWell® DOI product, a novel supplement targeting woman’s health including menopausal symptoms. We are also excited to continue to identify and progress on certain other potential novel therapeutic candidates, including our ongoing assessment of a number of novel immunomodulators developed by Yale University targeting major autoimmune diseases, as we announced earlier in the year,” said Mr. Ian Huen, Chief Executive Officer and Executive Director of Aptorum Group Limited.
Clinical Pipeline Update and Upcoming Milestones
In September 2021, Aptorum Group received clearance from the US FDA to open an IND to conduct clinical trials on SACT-1, an orally administered small molecule repurposed drug for the treatment of neuroblastoma. The IND-opening study is a bioavailability/Food Effect study, followed by a Phase 1b/2a trial in neuroblastoma patients which is subject to further FDA approval.
In May 2021, Aptorum Group announced its ongoing Phase I clinical trial for one of its lead programs, ALS-4, an orally administered small molecule drug for the treatment of infections caused by Staphylococcus aureus including MRSA, under which two initial cohorts of the SAD portion of the trial in healthy male and female adult subjects have been completed with no serious adverse events observed. In July 2021, the Company further announced two additional cohorts (Cohort C & D) of the SAD portion have been completed with no serious adverse events observed. In total, up to 6 cohorts for SAD and 3 cohorts for MAD have been planned. The MAD study is commencing in Q3, 2021.
In May 2021, Aptorum Group entered into an agreement with Exeltis regarding Aptorum’s preclinical asset targeting women’s health and gynaecological conditions, including endometriosis, in the European Union and Latin America. Aptorum retained development rights in the rest of the world.
In April 2021, Aptorum Group entered into a material transfer and license option agreement with Yale University to evaluate a group of preclinical stage novel immunomodulators that could represent first-in-class therapeutics in treating autoimmune and oncology diseases, among other indications.
Corporate Highlights
In May 2021, Jurchen Investments Limited, purchased an aggregate of 1,387,925 of the Company’s Class A Ordinary Shares at $2.882 per share, representing 10% premium to the last closing price.
On March 26, 2021, Aptorum Group entered into a Sales Agreement with H.C. Wainwright & Co., LLC, acting as the Company’s sales agent, pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, Class A Ordinary Shares for an aggregate offering price of up to $15,000,000.
Financial Results for the Six Months Ended June 30, 2021
Aptorum Group reported a net loss of $17.1 million for the six months ended June 30, 2021 compared to $7.0 million for the same period in 2020. The increase in net loss in the current period was driven by loss on investments in marketable securities, net of $7.6 million, and there was a gain on non-marketable investment of $1.6 million in the same period in 2020 while there was no such gain in current period.
Research and development expenses were $5.5 million for the six months ended June 30, 2021 compared to $4.3 million for the same period in 2020. The increase in research and development expenses was mainly due to the increase in services provided by contracted research organizations as a result of our projects’ development.
General and administrative fees were $2.6 million for the six months ended June 30, 2021 compared to $2.1 million for the same period in 2020. The increase in general and administration fees was mainly due to a one-off reversal of over-provision in relations to bonus payables to our directors, employees, external consultants and advisors in the last period. It was partly offset by the decrease in travelling expenses due to the outspread of COVID-19 and the decrease in amortization and depreciation due to the disposal of fixed assets in the second half of 2020.
Legal and professional fees were $1.2 million for the six months ended June 30, 2021 compared to $1.5 million for the same period in 2020. The decrease in legal and professional fees was mainly due to the decrease in consultancy services during current period.
As of June 30, 2021, cash and restricted cash totalled approximately $20.1 million and total equity was approximately $26.5 million.
Aptorum Group expects that its existing cash and restricted cash together with undrawn line of credit facility from related parties, will enable it to fund its operating and capital expenditure requirements for at least the next 12 months.
APTORUM GROUP LIMITED
CONDENSED CONSOLIDATED BALANCE SHEETS
(Stated in U.S. Dollars)
|
|
|
June 30, |
|
|
December 31, |
|
||
|
|
|
(Unaudited) |
|
|
|
|
||
|
ASSETS |
|
|
|
|
|
|
||
|
Current assets: |
|
|
|
|
|
|
||
|
Cash |
|
$ |
19,935,888 |
|
|
$ |
3,495,231 |
|
|
Restricted cash |
|
|
130,125 |
|
|
|
130,125 |
|
|
Digital currencies |
|
|
– |
|
|
|
1,539 |
|
|
Accounts receivable |
|
|
47,093 |
|
|
|
62,221 |
|
|
Inventories |
|
|
32,785 |
|
|
|
39,133 |
|
|
Marketable securities, at fair value |
|
|
702,937 |
|
|
|
28,384,944 |
|
|
Investments in derivatives |
|
|
– |
|
|
|
4,289 |
|
|
Amounts due from related parties |
|
|
113,858 |
|
|
|
– |
|
|
Due from brokers |
|
|
160,341 |
|
|
|
160,337 |
|
|
Other receivables and prepayments |
|
|
795,087 |
|
|
|
1,378,996 |
|
|
Total current assets |
|
|
21,918,114 |
|
|
|
33,656,815 |
|
|
Property, plant and equipment, net |
|
|
4,148,449 |
|
|
|
4,686,323 |
|
|
Operating lease right-of-use assets |
|
|
355,202 |
|
|
|
547,389 |
|
|
Non-marketable investments |
|
|
4,079,707 |
|
|
|
4,079,707 |
|
|
Intangible assets, net |
|
|
917,170 |
|
|
|
964,857 |
|
|
Long-term deposits |
|
|
296,225 |
|
|
|
296,225 |
|
|
Total Assets |
|
$ |
31,714,867 |
|
|
$ |
44,231,316 |
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND EQUITY |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES |
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
|
Amounts due to related parties |
|
$ |
133,761 |
|
|
$ |
145,926 |
|
|
Accounts payable and accrued expenses |
|
|
3,537,237 |
|
|
|
3,240,772 |
|
|
Finance lease liabilities, current |
|
|
50,881 |
|
|
|
49,396 |
|
|
Operating lease liabilities, current |
|
|
339,040 |
|
|
|
432,600 |
|
|
Total current liabilities |
|
|
4,060,919 |
|
|
|
3,868,694 |
|
|
Finance lease liabilities, non-current |
|
|
22,106 |
|
|
|
47,923 |
|
|
Operating lease liabilities, non-current |
|
|
63,008 |
|
|
|
155,121 |
|
|
Loan payables to related parties |
|
|
1,098,492 |
|
|
|
2,007,285 |
|
|
Total Liabilities |
|
$ |
5,244,525 |
|
|
$ |
6,079,023 |
|
|
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies |
|
|
– |
|
|
|
– |
|
|
|
|
|
|
|
|
|
|
|
|
EQUITY |
|
|
|
|
|
|
|
|
|
Class A Ordinary Shares ($1.00 par value; 60,000,000 shares authorized, 13,170,374 and 11,584,324 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively) |
|
$ |
13,170,374 |
|
|
$ |
11,584,324 |
|
|
Class B Ordinary Shares ($1.00 par value; 40,000,000 shares authorized, 22,437,754 shares issued and outstanding as of June 30, 2021 and December 31, 2020) |
|
|
22,437,754 |
|
|
|
22,437,754 |
|
|
Additional paid-in capital |
|
|
42,441,471 |
|
|
|
38,247,903 |
|
|
Accumulated other comprehensive income |
|
|
28,267 |
|
|
|
53,296 |
|
|
Accumulated deficit |
|
|
(46,570,550 |
) |
|
|
(30,489,126 |
) |
|
Total equity attributable to the shareholders of Aptorum Group Limited |
|
|
31,507,316 |
|
|
|
41,834,151 |
|
|
Non-controlling interests |
|
|
(5,036,974 |
) |
|
|
(3,681,858 |
) |
|
Total equity |
|
|
26,470,342 |
|
|
|
38,152,293 |
|
|
Total Liabilities and Equity |
|
$ |
31,714,867 |
|
|
$ |
44,231,316 |
|
APTORUM GROUP LIMITED
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(Stated in U.S. Dollars)
|
|
|
For the six months ended |
|
|||||
|
|
|
2021 |
|
|
2020 |
|
||
|
|
|
(Unaudited) |
|
|
(Unaudited) |
|
||
|
Revenue |
|
|
|
|
|
|
||
|
Healthcare services income |
|
$ |
637,784 |
|
|
$ |
327,273 |
|
|
Operating expenses |
|
|
|
|
|
|
|
|
|
Costs of healthcare services |
|
|
(629,987 |
) |
|
|
(436,171 |
) |
|
Research and development expenses |
|
|
(5,508,356 |
) |
|
|
(4,315,033 |
) |
|
General and administrative fees |
|
|
(2,564,117 |
) |
|
|
(2,076,634 |
) |
|
Legal and professional fees |
|
|
(1,240,512 |
) |
|
|
(1,540,304 |
) |
|
Other operating expenses |
|
|
(189,125 |
) |
|
|
(641,457 |
) |
|
Total operating expenses |
|
|
(10,132,097 |
) |
|
|
(9,009,599 |
) |
|
|
|
|
|
|
|
|
|
|
|
Other (loss) income |
|
|
|
|
|
|
|
|
|
(Loss) gain on investments in marketable securities, net |
|
|
(7,565,273 |
) |
|
|
192,134 |
|
|
Gain on non-marketable investment |
|
|
– |
|
|
|
1,635,939 |
|
|
Loss on investments in derivatives, net |
|
|
(4,289 |
) |
|
|
(101,233 |
) |
|
Gain on use of digital currencies |
|
|
4,918 |
|
|
|
– |
|
|
Interest expense, net |
|
|
(126,102 |
) |
|
|
(144,226 |
) |
|
Sundry income |
|
|
82,652 |
|
|
|
111,398 |
|
|
Total other (loss) income, net |
|
|
(7,608,094 |
) |
|
|
1,694,012 |
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(17,102,407 |
) |
|
$ |
(6,988,314 |
) |
|
Less: net loss attributable to non-controlling interests |
|
|
(1,020,983 |
) |
|
|
(783,749 |
) |
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable to Aptorum Group Limited |
|
$ |
(16,081,424 |
) |
|
$ |
(6,204,565 |
) |
|
|
|
|
|
|
|
|
|
|
|
Net loss per share – basic and diluted |
|
$ |
(0.47 |
) |
|
$ |
(0.21 |
) |
|
Weighted-average shares outstanding – basic and diluted |
|
|
34,280,137 |
|
|
|
29,956,393 |
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(17,102,407 |
) |
|
$ |
(6,988,314 |
) |
|
Other Comprehensive (loss) income |
|
|
|
|
|
|
|
|
|
Exchange differences on translation of foreign operations |
|
|
(25,029 |
) |
|
|
31,170 |
|
|
Other Comprehensive (loss) income |
|
|
(25,029 |
) |
|
|
31,170 |
|
|
Comprehensive loss |
|
|
(17,127,436 |
) |
|
|
(6,957,144 |
) |
|
Less: comprehensive loss attributable to non-controlling interests |
|
|
(1,020,983 |
) |
|
|
(783,751 |
) |
|
Comprehensive loss attributable to the shareholders of Aptorum Group Limited |
|
|
(16,106,453 |
) |
|
|
(6,173,393 |
) |
About Aptorum Group Limited
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The pipeline of Aptorum is also enriched through (i) the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases; and (ii) the co-development of a novel molecular-based rapid pathogen identification and detection diagnostics technology with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore’s Agency for Science, Technology and Research.
For more information about Aptorum Group, please visit www.aptorumgroup.com.
Disclaimer and Forward-Looking Statements
This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.
This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the US Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations.
These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future, as well as the prospectus that received the French Autorité des Marchés Financiers visa n°20-352 on 16 July 2020. As a result, the projections included in such forward-looking statements are subject to change and actual results may differ materially from those described herein.
Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
This announcement is not a prospectus within the meaning of the Regulation (EU) n°2017/1129 of 14 June 2017 as amended by Regulations Delegated (EU) n°2019/980 of 14 March 2019 and n°2019/979 of 14 March 2019.
This press release is provided “as is” without any representation or warranty of any kind.
Contacts
Aptorum Group Limited
Investor Relations Department
investor.relations@aptorumgroup.com
+44 20 80929299
Redchip – Financial Communications United States
Investor relations
Dave Gentry
dave@redchip.com
+1 407 491 4498
Actifin – Financial Communications Europe
Investor relations
Ghislaine Gasparetto
ggasparetto@actifin.fr
+33 1 56 88 11 22